Can immune therapy help rare muscle disorder?
NCT ID NCT06599697
First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times
Summary
This phase 2 trial tests whether intravenous immunoglobulin (IVIG) can help people with a rare autoimmune muscle disease called anti-HMGCR immune-mediated necrotizing myopathy. Twelve participants will receive either IVIG or a placebo every 4 weeks for 12 weeks, then all may receive IVIG in an open-label extension. The main goal is to see if IVIG lowers muscle enzyme levels and is safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Intravenous immunoglobulin (IVIG)
- What this could lead to
- If it works, this could point toward a treatment for a rare muscle disease that causes weakness and damage.
- What could go wrong
- This is a very small early-phase trial with only 12 people, so results may not apply widely. IVIG can cause side effects like headache, fever, or allergic reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTI-3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE (HMGCR) IMMUNE-MEDIATED NECROTIZING MYOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Johns Hopkins University
NOT_YET_RECRUITINGBaltimore, Maryland, 21218, United States
-
University of Alabama at Birmingham
RECRUITINGBirmingham, Alabama, 35233, United States
-
University of Pittsburgh
RECRUITINGPittsburgh, Pennsylvania, 15260, United States
-
University of Texas Health Science Center at Houston
RECRUITINGHouston, Texas, 77030, United States
-
University of Washington
ACTIVE_NOT_RECRUITINGSeattle, Washington, 98195, United States